What is Celldex Therapeutics, Inc. (CLDX)?

Celldex Therapeutics, Inc. (CLDX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CLDX?

The current price of CLDX is $30.15. Prices are updated in real time on Stocks360.

What is CLDX's price-to-earnings (PE) ratio?

CLDX's trailing twelve-month PE ratio is -6.92, based on current price and earnings per share data available on Stocks360.

What is CLDX's market capitalization?

CLDX's market capitalization is $2,367,664,425.00, placing it in the mid-cap tier.

Celldex Therapeutics, Inc. (CLDX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$30.15

Market Cap

$2.37B

PE (TTM)

-6.92

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.90

Day Range

$29.33 – $30.34

52-wk Range

$22.10 – $45.14

Avg Volume

N/A

Volume

746.58K

Celldex Therapeutics, Inc. (CLDX) is a publicly traded company in the Healthcare sector. Latest price: $30.15. Market cap $2.37B. Trailing PE -6.92. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-28 · $27.06 2026-10-27 · $30.15 (+11.42%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.94 vs est. $-1.06

Beat by $0.12

Next Earnings

Nov 9, 2026

EPS estimate $-1.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.92×
P/S (TTM)	21139.86×
P/B	3.28×
PEG	0.20×
P/FCF (TTM)	-9.79×
EV / EBITDA	-7.82×
EV / Sales	20759.95×
Earnings Yield	-12.81%
Free Cash Flow Yield	-10.21%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.33B
Revenue (TTM)	$112.00K
Net Income (TTM)	-$303.25M
Free Cash Flow (TTM)	-$241.82M
Net Debt	-$42.55M
Working Capital	$663.61M
Gross Margin	-56850.89%
Operating Margin	-290948.21%
Net Margin	-268385.71%
Return on Equity	-52.36%
Return on Invested Capital	-45.10%